Business Wire · LYT · October 19, 2026

PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: Business Wire ↗